Drawing based on the label description. No photo yet.
“Nadolol and bendroflumethiazide tablets, 40 mg/5 mg, contain 40 mg nadolol combined with 5 mg bendroflumethiazide, and are white to off-white, round, bi-convex tablets debossed with "G" bisect "531" on one side and plain on the other”
G 531 pill
Pill with imprint G 531 is white, round, 9 mm and has been identified as Nadolol and Bendroflumethiazide 40 mg / 5 mg. It is used for high blood pressure. It is supplied by Impax Generics.
Nadolol and Bendroflumethiazide 40 mg / 5 mg
- Imprint
- G 531
- Strength
- Nadolol 40 mg / Bendroflumethiazide 5 mg
- Used for
- High blood pressure
- Color
- White
- Shape
- Round
- Size
- 9 mm
- Score
- Breaks into 2 pieces
- Form
- Tablet
- Manufacturer
- Impax Generics
- Drug class
- Beta blocker (heart and blood pressure medicine)
- NDC
- 0115-5311, 0115-5311-01, 0115-5311-02
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Nadolol and Bendroflumethiazide used for?
Nadolol and Bendroflumethiazide is used for high blood pressure.
- Medicine type
- Beta blocker (heart and blood pressure medicine); thiazide diuretic (water pill)
Official uses from the US prescribing label
Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components.
From the FDA-approved label on DailyMed (published Apr 18, 2016).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows G 531 and the other side is plain.
- It is white, round, 9 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Ingredients
Active: Nadolol, Bendroflumethiazide
Inactive: Croscarmellose Sodium, Hypromelloses, Lactose Monohydrate, Magnesium Stearate, Mannitol, Cellulose, Microcrystalline, Starch, Corn, Talc
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
0115 2790
Chloroquine Phosphate 250 mg
White, round, 10 mm
Used for rheumatoid arthritis and amoeba infection
-
CN250
Chloroquine Phosphate 250 mg
White, round, 10 mm
Used for rheumatoid arthritis and amoeba infection
-
A63
Everolimus 3 mg
White, round, 10 mm
Used for seizures
-
A62
Everolimus 2 mg
White, round, 9 mm
Used for seizures
-
AA 79
Nadolol 40 mg
White, round, 9 mm
Used for high blood pressure and heart failure
-
ZYLOPRIM 200
Allopurinol 200 mg
White, round, 9 mm
Used for gout